Literature DB >> 12672221

Rheumatology outcomes: the patient's perspective.

Alison Carr1, Sarah Hewlett, Rod Hughes, Helene Mitchell, Sarah Ryan, Maggie Carr, John Kirwan.   

Abstract

Our aim was to explore the patient's perspective of outcomes in rheumatoid arthritis (RA) to identify which outcomes are important to patients and how patients calibrate what constitutes a meaningful change in those outcomes. A qualitative study was performed using focus groups in 5 clinical centers in different geographical locations in the UK. Each group contained 6 to 9 patients with RA who were purposefully sampled to include men and women with a range of age, disease duration, functional disability, work disability, and current disease activity. Each focus group lasted around 1 h and addressed 3 questions: What outcomes from treatment are important to RA patients? What makes patients satisfied or dissatisfied with a treatment? How do patients decide that a treatment is working? Patients identified as important not only physical outcomes such as pain and disability, but also fatigue and a general feeling of wellness. The relative importance of these outcomes depended on the stage of disease and on specific situations, such as a disease flare. Satisfaction was influenced by communication, access to treatment, and treatment efficacy. Treatment efficacy was related to symptom reduction, with the magnitude of reduction necessary for efficacy dependent on the stage of disease. For example, large changes were deemed necessary with disease of long duration, while in early disease, even small changes could be important. Our data support existing knowledge of the importance of pain and mobility as treatment outcomes, but raise new and important issues: Some outcomes of importance to patients are not currently measured and there are no measures available to capture them. Existing measures need to be calibrated to take account of the differing importance of outcomes at different stages of disease and variations in the magnitude of change within the same outcome that indicate treatment efficacy.

Entities:  

Mesh:

Year:  2003        PMID: 12672221

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  81 in total

1.  Association Between Measures of Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis and Osteoarthritis.

Authors:  Marita Cross; Helen Lapsley; Annica Barcenilla; Peter Brooks; Lyn March
Journal:  Patient       Date:  2008-04-01       Impact factor: 3.883

2.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

3.  Patients' perceptions of health related quality of life in rheumatoid arthritis and chronic low back pain.

Authors:  Montserrat Núñez; Alex Sanchez; Esther Nuñez; Teresa Casals; Cayetano Alegre; José Muñoz-Gomez
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

Review 4.  The COMET Handbook: version 1.0.

Authors:  Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young
Journal:  Trials       Date:  2017-06-20       Impact factor: 2.279

5.  Patient and public involvement in patient-reported outcome measures: evolution not revolution.

Authors:  Sophie Staniszewska; Kirstie L Haywood; Jo Brett; Liz Tutton
Journal:  Patient       Date:  2012       Impact factor: 3.883

6.  Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Authors:  D van der Heijde; L Klareskog; A Singh; J Tornero; J Melo-Gomes; C Codreanu; R Pedersen; B Freundlich; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

7.  Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment.

Authors:  Peter M ten Klooster; Martine M Veehof; Erik Taal; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

8.  Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis.

Authors:  Markus H Hoffmann; Rudolf Hopf; Birgit Niederreiter; Heinz Redl; Josef S Smolen; Günter Steiner
Journal:  Arthritis Res Ther       Date:  2010-03-11       Impact factor: 5.156

9.  Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.

Authors:  Johanna M Hazes; Peter Taylor; Vibeke Strand; Oana Purcaru; Geoffroy Coteur; Philip Mease
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

10.  Validation of the International Classification of Functioning, Disability and Health Core Set for chronic widespread pain from the perspective of fibromyalgia patients.

Authors:  Robin Hieblinger; Michaela Coenen; Gerold Stucki; Andreas Winkelmann; Alarcos Cieza
Journal:  Arthritis Res Ther       Date:  2009-05-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.